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Low heritability in pharmacokinetics of
talinolol: a pharmacogenetic twin study on
the heritability of the pharmacokinetics of
talinolol, a putative probe drug of MDR1
and other membrane transporters
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Abstract
Background: Efflux transporters like MDR1 and MRP2 may modulate the pharmacokinetics of about 50 % of all
drugs. It is currently unknown how much of the variation in the activities of important drug membrane transporters
like MDR1 or MRP2 is determined by genetic or by environmental factors. In this study we assessed the heritability
of the pharmacokinetics of talinolol as a putative probe drug for MDR1 and possibly other membrane transporters.
Methods: Talinolol pharmacokinetics were investigated in a repeated dose study in 42 monozygotic and 13
same-sex dizygotic twin pairs. The oral clearance of talinolol was predefined as the primary parameter. Heritability
was analyzed by structural equation modeling and by within- and between-subject variance and talinolol clearance
was correlated with polymorphisms in MDR1, MRP2, BCRP, MDR5, OATP1B1, and OCT1.
Results: Talinolol clearance varied approximately ninefold in the studied sample of healthy volunteers. The
correlation of clearances between siblings was not significantly different for the monozygotic and dizygotic pairs.
All data analyses consistently showed that variation of talinolol pharmacokinetics was mainly determined by
environmental effects. Structural equation modeling attributed 53.5 % of the variation of oral clearance to common
environmental effects influencing both siblings to the same extent and 46.5 % to unique environmental effects
randomly affecting individual subjects. Talinolol pharmacokinetics were significantly dependent on sex, body mass
index, total protein consumption, and vegetable consumption.
Conclusions: The twin study revealed that environmental factors explained much more of the variation in
pharmacokinetics of talinolol than genetic factors.
Trial registration: European clinical trials database number: EUDRA-CT 2008-006223-31. Registered 26 September 2008.
ClinicalTrials.gov number: NCT01845194.
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Background
Efflux transmembrane transport of drugs and other mol-
ecules is highly variable within and between humans due
to inherited and environmental factors. This can have
profound consequences for the intended and adverse ef-
fects of drugs and for the biological effects of many other
endogenous and exogenous molecules. Efflux trans-
porters first came into focus as mediators of multi-drug
resistance in cancer chemotherapy [1, 2]. Among the
efflux transporters, multi-drug resistance protein 1
(MDR1, P-glycoprotein), encoded by the ABCB1 gene,
has been the most extensively studied [3–9]. MDR1 is
expressed on the apical membrane of enterocytes, he-
patocytes, and renal tubular cells and at the blood–
brain barrier and the blood–testes barrier and protects
cells and organs against overload with numerous sub-
stances [10, 11]. Some animals completely lack MDR1
but we do not know of any humans completely lacking
it [10]. Nevertheless, MDR1 expression and activity
vary substantially between individuals. MDR1 expres-
sion is regulated by several mechanisms and substantial
up-regulation can be induced by several substances and
is mediated by PXR, RXR, and other nuclear transcrip-
tion factors [12]. On the other hand, numerous envir-
onmental substances and drugs, such as cyclosporine
or verapamil, can substantially inhibit P-glycoprotein
[13, 14].
Inherited polymorphisms may contribute to variation in
MDR1 activity. In particular, the polymorphisms C1236T
(silent), G2677T/A (Ala893Ser/Thr), and C3435T (silent)
have been extensively studied [15–24]. Understanding of
the functional role of these variants in humans is compli-
cated by the fact that these variants are in strong linkage
disequilibrium [25, 26]. Genetic polymorphisms may play
some role in the variation of MDR1 expression and activ-
ity. However, the genotype–phenotype correlation data
obtained by different investigators is not entirely consist-
ent. In conclusion, it is currently unknown how much of
the variation in MDR1 activity as tested in vivo with puta-
tive probe drugs like talinolol or digoxin is explained by
environmental or heritable factors.
Another efflux transporter of particular interest for the
disposition of drugs, other foreign compounds, and en-
dogenous substrates is the multidrug resistance-associated
protein 2 (MRP2; also known as ABCC2 (ATP binding
cassette subfamily C member 2)). MRP2 is expressed in
a broad range of tissues and also contributes to multi-
drug resistance in cancer therapy [27]. It is expressed
on the apical membrane of cells in the liver, intestine,
and kidneys [28, 29]. MRP2 is an important efflux
transporter of conjugated bilirubin and inherited lack
of activity is known as Dubin–Johnson syndrome [30].
Furthermore, MRP2-mediated drug interactions may
cause liver toxicity [31]. Activity of MRP2 can also be
greatly modified by transcriptional regulation and by
inhibition of its transport function, but also by genetic
polymorphisms. Among others, the impact of two genetic
polymorphisms (-C24T and G1249A in MRP2) on, for
example, the bioavailability of mycophenolate mofetil
[32, 33] and tacrolimus [34, 35], have been extensively
studied, with controversial results.
A number of probe drugs for the in vivo study of
MDR1 activity have been suggested but none of them is
perfect [36, 37]. Because of the low substrate specificity
of many drug membrane transporters, many probe drugs
may reflect the activity of several transporters. For in-
stance, a typical probe drug for MDR1, fexofenadine, is
also a substrate of several OATP influx transporters
[37]. In this study, talinolol was chosen as a probe drug
for drug membrane transporters. Talinolol appears suit-
able as a membrane transporter probe drug since less
than 1 % of an orally administered dose was recovered
as metabolites in urine [38, 39]; thus, metabolism plays
only a minor role in its elimination.
Evidence for which transporters are possibly relevant
in the pharmacokinetics of talinolol is based on multiple
data sources. Talinolol is widely considered as an MDR1
probe drug both in vitro and in vivo [36]. Several investi-
gators used talinolol in caco-2 cells as a model substrate
of MDR1. Plasma concentrations after oral administra-
tion of talinolol were substantially (4.5-fold) higher in a
MDR1 knockout rat compared with the wild-type rat
[40]. Clinically, net intestinal secretion of talinolol was
inhibited by the MDR1 inhibitor verapamil [41] and car-
bamazepin [42]. Additionally, rifampin-induced MDR1
and MRP2 expression resulted in decreased oral bio-
availability of talinolol [43] and corresponding effects
were seen with St. John’s wort [44]. Unexpectedly, two
inhibitors of MDR1, grapefruit juice and verapamil, de-
creased oral bioavailability of talinolol, which was ex-
plained by preferential inhibition of intestinal influx
transporters by polytropic inhibitors like verapamil [45,
46]. According to these data, it is very likely that MDR1
modulates the pharmacokinetics of talinolol in humans
to a relevant extent.
MRP2 may also modulate the pharmacokinetics of tali-
nolol. Expression of both MDR1 and MPR2 is greatly
increased by typical inducers like carbamazepin and
rifampin and the effects of these inducers on talinolol
pharmacokinetics may thus also be explained by an
involvement of MRP2. This is also supported by the
low talinolol oral bioavailability found in carriers of the
MPR2 exon 10 Val417Ile genotype (G1249A) [47].
A comprehensive in vitro screen of all influx and ef-
flux transporters possibly relevant in talinolol pharma-
cokinetics has not been performed to our knowledge.
Preliminary data indicated that talinolol may be a sub-
strate of OATP1B1 [48] and with its cationic structure,
Matthaei et al. Genome Medicine  (2016) 8:119 Page 2 of 12
talinolol may be a substrate of OCT1. In addition, other
efflux transporters, including the polymorphic MDR5
(ABCB5) and BCRP (ABCG2) [49], may modulate the
pharmacokinetics of talinolol; therefore, we also explore
here the impact of polymorphisms known to be func-
tional in these transporters.
The aim of the present study was to reveal how much
of the variation in talinolol pharmacokinetics is due to
heritable factors. Secondary questions were whether we
can reproduce the effects of genetic polymorphisms
which were associated with talinolol pharmacokinetics
in earlier publications and how suitable a much lower
test dose of talinolol (2.5 mg) might be for in vivo phe-
notyping. A low dose is apparently more safe and the
lower dose was also scientifically interesting because the
impact of MDR1 on talinolol pharmacokinetics might
depend on the dose [50].
Methods
Subjects and study design
Monozygotic (MZ) and same-sex dizygotic (DZ) twin
pairs were included if they were healthy according to
medical history, clinical examination, electrocardiogram,
and standard clinical biochemistry and hematology tests.
Except for oral contraceptives no other drugs were
allowed for 1 week prior to and 48 h after administration
of talinolol.
A single dose of 50 mg talinolol (Cordanum®, AWD.-
pharma, Dresden, Germany) was administered to 114
subjects. Among these subjects were 43 MZ and 13 DZ
twin pairs; two single twins were excluded from the ana-
lyses since the second twin could not participate in the
study. Additionally, one MZ pair was excluded from the
analyses because of missing concentration data for the
last blood sample 22 h after talinolol administration.
Therefore, all analyses on 50 mg talinolol are based on
data from 110 subjects (42 MZ and 13 DZ twin pairs).
Per protocol, talinolol 50 mg was administered on three
different occasions to each subject with an at least 7-day
wash-out period in between. Blood sampling was done
prior to and 0.5, 1, 2, 3, 4, 5, 6, and 22 h after talinolol
administration. Talinolol was part of a phenotyping drug
cocktail in which midazolam, torsemide, metoprolol (all
intravenously) [51], and caffeine (orally) [52] were also
administered in a sequential order in the first 2 h of each
study day. All the substances in this cocktail are not
known to have any pharmacokinetic interactions and
talinolol was the last administered drug and was given
1 h after caffeine.
In an additional add-on study aiming to compare low-
dose talinolol, which is presumed to lack relevant cardio-
vascular effects, 2.5 mg talinolol was administered to 73
subjects: 29 MZ and 7 DZ twin pairs. One single twin was
excluded from the analyses. The capsules containing
2.5 mg of talinolol were prepared from Cordanum® 50
tablets, which were ground and used to refill gelatin cap-
sules in 2.5 mg portions. In this add-on study, blood sam-
pling was done prior to and 0.5, 1, 1.5, 2, 3, 4, 6, and 8 h
after talinolol administration.
Blood samples were centrifuged for 10 minutes
(4000 rpm, 4 °C) and plasma samples were stored at
−20 °C until laboratory analysis.
Talinolol plasma concentrations
Talinolol plasma concentrations were determined by
liquid chromatography–tandem mass spectrometry (LC-
MS/MS) analysis using deuterium labeled talinolol-d5
(Toronto Research Chemicals, Nr. T005002) as internal
standard. For the 50 mg talinolol study sample prepar-
ation with protein precipitation and HPLC separation
were performed as described [51]. Samples from the low-
dose study were worked up with solid phase extraction.
LC-MS/MS analysis was carried out on an Agilent 6460
triple quadrupol mass spectrometer (Agilent, Waldbronn,
Germany) coupled to an Agilent 1200 HPLC system.
Ionization mode was electrospray (ESI), polarity positive.
The mass spectrometer was operated in the multiple reac-
tion monitoring (MRM) mode using the transitions m/z
364.3 to 308 and m/z 369.3 to 313 for talinolol and the
internal standard, respectively. For the 50-mg dose
study, the limit of quantification (LOQ) was 1.5 pmol/
ml. Quality control samples over the whole concentra-
tion range could be determined with a coefficient of
variation (CV) better than 2.1 %. For the low-dose
study, the LOQ was 0.2 pmol/ml. Over the whole con-
centration range (from 0.2 to 30 pmol/ml), a CV better
than 5 % was achieved.
Molecular genetic analyses
Genotyping was performed by single-base primer ex-
tension using fluorescence-labeled dideoxynucleotides
followed by capillary electrophoresis. Genotype calling
was performed using Gene Mapper v3.7 Software ®
(Applied Biosystems ®, Foster City, CA, USA). The
following variants of efflux transporters were genotyped:
MDR1 C1236T (rs1128503), G2677T/A (rs2032582), and
C3435T (rs1045642); MDR5 C392T (rs17143212); MRP2
G1249A (rs2273697) and -C24T (rs717620), BCRP
(ABCG2) G34A (rs2231137) and C421A (rs2231142).
Additionally, the following haplotypes of the influx trans-
porters were determined: OATP1B1 *1a, *1b, *5, *14, *15,
and OCT1 alleles *1 to *10. In total, variants in 23 poly-
morphic genes were genotyped for assessment of zygosity.
Monozygosity was concluded when both siblings of each
pair had completely identical genotypes for all 23 poly-
morphic loci.
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Statistics
Pharmacokinetic parameters were estimated with
WinNonlin (Pharsight Corporation, Mountain View,
USA). Total clearance, the primary parameter, normalized
to bioavailability (Cl/F) was calculated as dose/AUCinfinity
and in this study is referred to as “clearance”. The area
under the concentration time curve (AUC) was calculated
by the linear/log trapezoidal rule. AUCinfinity values were
extrapolated based on the last predicted concentration
using the terminal elimination rate constant (lambda z).
AUC7h reflects the AUC in the first 7 h after dosage.
Maximum concentration (Cmax) and time of maximum
concentration (tmax) are given as measured. The ter-
minal half-life (t1/2) was calculated as ln(2)/lambda z.
The volume of distribution based on the terminal phase
(Vz) was calculated as Dose/(lambda z × AUCinfinity).
Heritability was estimated by structural equation model-
ing using the “mets” package for the statistical program-
ming environment R [53, 54]. Variation in clearance was
decomposed into additive genetic effects (A), dominant
genetic effects (D), common environmental effects (C),
and unique environmental effects (E). Fit of the models
ACE, ADE, AE, and CE was tested by the Akaike-
information criterion (AIC). In addition, the repeated ad-
ministration of 50 mg talinolol to each subject was used
to calculate the genetic component (rGC) as described by
Kalow et al. [55, 56]. Variance within (Vw) the subjects
and variance between (Vb) the subjects were calculated
for all subjects who received 50 mg talinolol on three
different occasions. The mean of 50 calculations of rGC is
given. For each calculation of rGC only one randomly se-
lected sibling of each pair was used, since the two siblings
of each twin pair are not independent units.
The non-parametric Mann–Whitney U test was used
for comparison of two groups and the Jonckheere–
Terpstra test for comparison of more than two groups.
In the analyses of the effects of genetic polymorphisms
on talinolol clearance, an adjustment for multiple testing
was done by using the Bonferroni correction method. Due
to the high number of tests on genetic polymorphisms
(ten in total), significance was determined if p < 0.005.
Multiple linear regression analysis was performed for
evaluating the effects of the genetic polymorphisms as
well as the confounders sex, age, body mass index,
consumption of protein, and consumption of vegetables.
Protein and vegetable consumption was recorded using
validated nutrition questionnaires [57] and calculated as
the mean of items “meat”, “sausage”, “fish”, “dairy prod-
ucts”, and “eggs” and as the mean of items “salad and raw
vegetable” and “cooked vegetable”, respectively.
Results
Heritability of the variation in pharmacokinetics of talino-
lol was studied in 110 volunteers (42 monozygotic (MZ)
and 13 dizygotic (DZ) twin pairs). No serious adverse
events related to the study medication were reported. No
statistically significant differences in the demographic data
between MZ and DZ twin pairs were observed (Additional
file 1).
Talinolol total clearance (Cl/F) measured after 50 mg
talinolol varied 3.8-fold (in DZ) and 8.8-fold (in MZ);
after adjustment for body weight, variation in clearance
remained high with 2.9-fold and 6.3-fold in DZ and MZ
twins, respectively. Similarly, strong variation was ob-
served in AUCinfinity and AUC7h (Table 1).
Table 1 Pharmacokinetic parameters of talinolol (50 mg dose)
MZ twin pairs DZ twin pairs
Parameter Unit Mean ± SD Median (Min–Max)
Ratio Max/Min
Mean ± SD Median (Min–Max)
Ratio Max/Min
Clearance (Cl/F) l/min 0.97 ± 0.42 0.87 (0.30–2.64)
8.8
0.82 ± 0.27 0.76 (0.37–1.39)
3.8
Clearance per body weight (Cl/F/kg) ml/min/kg 14.4 ± 5.51 13.5 (6.16–38.5)
6.3
12.1 ± 3.8 11.6 (6.96–19.9)
2.9
AUCinfinity mg*min/l 62.8 ± 25.2 60.2 (22.8–171.1)
7.5
71.3 ± 23.8 68.6 (37.6–135.8)
3.6
AUC7h mg*min/l 20.1 ± 9.10 19.3 (7.36–62.7)
8.5
24.9 ± 9.93 23.6 (11.7–54.8)
4.7
Central volume of distribution (Vz) l 1115 ± 510 1006 (293–2549)
8.7
889 ± 449 747 (302–2169)
7.2
Maximum plasma concentration (Cmax) μg/l 94.3 ± 47.0 84.9 (23.3–258)
11.1
124 ± 55.4 115 (51.9–269)
5.2
Time of maximum plasma concentration (tmax) h 2.6 ± 0.7 2.6 (1.2–4.1)
3.4
2.6 ± 0.8 2.7 (1.0–3.9)
3.9
Terminal elimination half life (t1/2) h 13.3 ± 4.0 12.2 (7.9–30.0)
3.8
11.9 ± 2.7 11.5 (7.2–18.1)
4.3
MZ monozygotic, DZ dizygotic, SD standard deviation. All pharmacokinetic parameters were calculated with the mean of up to three study days for each subject
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No sequence effects were observed, i.e., the mean
pharmacokinetic parameters were not significantly dif-
ferent between the study days. Clearance varied within
subjects up to threefold between the three different
study days (Fig. 1a) and the between-subject coefficient
of variation (CV) was about 42 % for the whole study
population. Within-twin pair correlations of the clear-
ance were not significantly different between DZ and
MZ twin pairs. With Pearson’s correlation coefficients of
0.65 (95 % confidence interval (CI) 0.43–0.80) for MZ
and 0.82 (95 % CI 0.49–0.94) for DZ correlation, the
correlation was unexpectedly nominally even higher in
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Fig. 1 a Variation in Cl/F for the subjects who performed all three study days (SD) of the 50 mg talinolol study phase. b, c Correlation of the Cl/F
after administration of 50 mg talinolol for all siblings from MZ (n = 42) and DZ (n = 13) twin pairs. d, e Correlation of the AUC7h after
administration of 50 mg talinolol (filled circles) and the dose-adjusted AUC7h after administration of 2.5 mg talinolol (empty circles) for all
analyzed twins. For b–d the Pearson correlation coefficients, the coefficients of determination, and the p-values are given. MZ monozygotic
twin pairs, DZ dizygotic twin pairs, Cl/F total plasma clearance/bioavailability, AUC7h area under the curve in the first 7 h after application, SD
study day
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DZ than in MZ twin pairs (Fig. 1b, c). This indicates that
common environmental effects substantially influenced
the variation of the clearance.
According to structural equation modeling, common
environmental (C) and unique environmental effects (E)
best explained the variation in the clearance of talinolol
(Table 2). Common environmental effects seem to ac-
count for 53.5 % and unique environmental effects for a
further 46.5 % of the variation in the clearance (Table 2).
An alternative model (AE) explained 50 % of the vari-
ation by additive genetic effects and 50 % by environmen-
tal effects. However, statistically this model was clearly
inferior according to the AIC.
The pharmacokinetics of drugs usually depends on body
weight and body weight is partially also genetically deter-
mined. Results were similar after adjustment of talinolol
clearance for body weight with slightly more unique envir-
onmental effects (C = 45 % (95 % CI 24–66 %), E = 55 %
(95 % CI 34–76 %)).
An alternative indicator for heritability can be esti-
mated from the comparison of within- and between-
subject variation. Based on the within- and between-
subject variance with the three times repetition of 50 mg
talinolol, the genetic component (rGC) was 0.38 (95 %
CI 0.35–0.41) for talinolol total oral clearance and 0.53
(95 % CI 0.50–0.57) for talinolol AUC (Table 3). Within-
and between-subject variance was similar for tmax and
Cmax, which indicates there were no relevant genetic in-
fluences on these two parameters (Table 3).
Although our study indicated only low to moderate
heritability in talinolol pharmacokinetic variation, there
may be up to 38 % heritability in the clearance according
to the repeated measurement approach. Therefore, we
evaluated the influence of genetic polymorphisms on the
efflux transporters MDR1, MDR5, MRP2, and BCRP as
well as the most relevant polymorphisms in the influx
transporters OCT1 and OATP1B1 on talinolol clearance.
Considering the moderate sample size of our study, only
those polymorphisms which have been associated with
transport activity in earlier studies were analyzed. Het-
erozygous or homozygous carriers of MDR1 1236 T al-
leles and MDR1 2677 T alleles showed a significant
increase (p = 0.0025 and 0.0015, respectively) in the
total oral clearance of talinolol (Table 4). Clearance was
increased by 44 and 48 % in homozygous carriers of
MDR1 1236 T and 2677 T alleles compared to homozy-
gous carriers of 1236C or 2677G alleles, respectively.
All other polymorphisms in the genes coding for the ef-
flux transporters MDR1, MRP2, MDR5, and BCRP were
not significant predictors of talinolol total oral clear-
ance (Table 4). Concerning the influx transporters
OATP1B1 and OCT1, after adjustment for multiple
testing, none of the variants known to be functional
showed any significant association with talinolol clear-
ance (Additional file 2).
Multiple linear regression analysis was performed to
evaluate the possible influences of demographic and en-
vironmental factors potentially modulating the in vivo
activity of drug membrane transporters (Table 5). In
this multifactorial analysis none of the genetic polymor-
phisms remained significant, but sex, body mass index,
protein, and vegetable consumption significantly ex-
plained variation in the talinolol clearance; these factors
each explained only about 4 % of the total oral clear-
ance of talinolol.
In addition to the 50 mg study, a low-dose study using
2.5 mg talinolol was performed. This study included 29
MZ and 7 DZ twin pairs. To enhance the feasibility of
phenotyping, we restricted blood sampling to a shorter
interval and therefore AUC7h was the primary param-
eter. The median of the AUC7h was 0.58 mg*min/l and
varied between 0.36 and 1.42 mg*min/l. Between-twin
pairs Pearson’s correlation coefficients of the AUC7h
were similar for both the 50-mg and the 2.5-mg groups
(for 50 mg MZ = 0.73, DZ = 0.71; for 2.5 mg MZ = 0.71,
DZ = 0.74; Fig. 1d, e). Structural equation modeling
Table 2 Heritability of talinolol clearance (50 mg dose) according to structural equation modeling
Model A D C E Chi2 p AIC
(95 % CI) (95 % CI) (95 % CI) (95 % CI)
Saturated - - - - - - 63.67
ACE 0.00
(0.00–0.00)
- 0.535
(0.346–0.724)
0.465
(0.276–0.654)
36.9 0.001 70.60
ADE 0.500
(0.282–0.717)
0.00
(0.00–0.00)
- 0.500
(0.282–0.717)
39.6 <0.001 73.30
AE 0.500
(0.282–0.717)
- - 0.500
(0.282–0.717)
39.6 <0.001 71.30
CE - - 0.535
(0.346–0.724)
0.465
(0.276–0.654)
37.9 0.002 68.60
A additive genetic effects, D dominant genetic effects, C common environmental effects, E unique environmental effects, 95 % CI 95 % confidence interval, Chi2
chi-square value, AIC Akaike information criterion. P values were calculated with respect to the saturated model. The best fitting model (CE, bold text) was chosen
based on the lowest AIC
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revealed that variation of the AUC7h was best explained
by common environmental effects (68.5 %, 95 % CI
51.1–85.8 %) and unique environmental effects (31.5 %,
95 % CI 14.2–48.9 %).
While significant inter-individual variation in the time
of maximum blood concentration was observed after ad-
ministration of 50 mg talinolol (Fig. 2a), variation in the
time–concentration curves was apparently much lower
in the 2.5 mg group (Fig. 2b). After 50 mg talinolol, the
time of maximum plasma concentration (tmax) varied be-
tween 1 and 4.1 h whereas after 2.5 mg, tmax was 4 h
after administration in all 72 subjects (Fig. 2a, b). The
maximum plasma concentration (Cmax) after 2.5 mg tali-
nolol administration was 3.94 μg/l (median) and varied
between 1.67 and 13.2 μg/l. Accordingly, the dose ad-
justed Cmax was 1.57 μg/l/mg in the 2.5-mg study phase
and 1.85 μg/l/mg in the 50-mg study phase.
The AUC7h for the 50-mg and the 2.5-mg study
phases showed a significant (p = 0.035) but only weak
correlation, with a Person’s correlation coefficient of
0.25 (95 % CI 0.18–0.45) (Fig. 2c). Thus, according to
the coefficient of determination, only about 6 % of the
variation observed after administration of either dose
was predictive for the variation in the other dose.
Discussion
The impact of genetic variation on the activities of MDR1
and MRP2 has been extensively studied in the past
20 years but is still controversial [10, 11]. Conflicting re-
sults have been reported, particularly for the abundant
and widely studied variants in MDR1 (C1236T, G2677T/
A, and C3435T) as well as for the -C24T and G1249A var-
iants in MRP2 [10]. Also, the genotype–phenotype corre-
lations for many other frequent variants have mostly not
been consistently reproduced, whereas those variants with
strong penetrance and clear genotype–phenotype correla-
tions are relatively rare. In this situation, we went back in
the logical sequence of research to the important first
Table 3 Heritability of talinolol pharmacokinetics (50 mg dose)
according to the genetic component (rGC)
Vb Vw rGC (95 % CI)
Cl/F 0.100 0.062 0.38 (0.35–0.41)
AUC 476.9 225.2 0.53 (0.50–0.57)
Cmax 1617 1671
tmax 0.50 0.63
rGC genetic component, Cl/F total plasma clearance/bioavailability, AUC area
under the curve, Cmax maximum plasma concentration, tmax time of maximum
plasma concentration, Vb variance between the subjects, Vw variance within
each subject, 95 % CI 95 % confidence interval. The genetic component was
calculated as rGC = (Vb − Vw)/Vb as proposed by Kalow [52, 53].
Table 4 Influence of genetic polymorphisms in genes coding
for efflux transporters on talinolol clearance
Gene Genetic
polymorphism
Variant Genotype frequency
(n) [%]
Clearance
[l/min]
MDR1 C1236T C/C 31 (34) 0.77 ± 0.28
rs1128503 C/T 47 (52) 0.96 ± 0.37a
T/T 21 (24) 1.11 ± 0.50a
G2677T/A G/G 29 (32) 0.77 ± 0.29
(Ala893Ser/Thr) G/T 47 (52) 0.96 ± 0.37b
rs2032582 T/T 20 (22) 1.14 ± 0.50b
G/A 2 (2) 0.74 ± 0.03
A/A 0 (-) -
T/A 2 (2) 0.75 ± 0.10
C3435T C/C 19 (21) 0.83 ± 0.28
rs1045642 C/T 62 (68) 0.97 ± 0.44
T/T 19 (21) 0.92 ± 0.30
MDR5 C392T (Thr131Ile) C/C 89 (98) 0.92 ± 0.37
rs17143212 C/T 11 (12) 1.07 ± 0.54
T/T 0 (-) -
MRP2 -C24T C/C 73 (80) 0.92 ± 0.39
rs717620 C/T 21 (23) 1.03 ± 0.41
T/T 6 (7) 0.73 ± 0.33
G1249A (Val417Ile) G/G 68 (75) 0.95 ± 0.41
rs2273697 G/A 30 (33) 0.89 ± 0.37
A/A 2 (2) 0.97 ± 0.05
ABCG2 G34A (Val12Met) G/G 96 (105) 0.94 ± 0.40
rs2231137 G/A 4 (5) 0.84 ± 0.25
A/A 0 (-) -
C421A (Gln141Lys) C/C 75 (82) 0.94 ± 0.37
rs2231142 C/A 25 (28) 0.91 ± 0.46
A/A 0 (-) -
Data are given in mean ± standard deviation. aThere were significant
differences between heterozygous (C/T) and homozygous (T/T) carriers of the
MDR1 1236 T allele and homozygous carriers of the 1236C allele (C/C) as
tested with the Jonckheere–Terpstra test (p = 0.0025). bThere were significant
differences between heterozygous (G/T) and homozygous (T/T) carriers of the
MDR1 2677 T allele and homozygous carriers of the 2677G allele (G/G) as tested
with the Jonckheere–Terpstra test (p = 0.0015). Significance was determined after
correction for multiple testing for p < 0.005 (Bonferroni correction)
Table 5 Multiple linear regression analysis of talinolol (50 mg)
clearance
Factor r (r2)a Coefficient p
All factors 0.55 (0.30) - <0.001
Sex 0.20 (0.04) 0.184 0.044
Age 0.02 (<0.01) 0.001 NS
Body mass index 0.20 (0.04) 0.022 0.041
Protein consumption −0.20 (0.04) −0.144 0.046
Vegetable consumption −0.20 (0.04) −0.114 0.050
MDR1 C1236T −0.05 (<0.01) −0.039 NS
MDR1 G2677T/A −0.03 (<0.01) −0.020 NS
NS not significant. aThe correlation is given for the total model with all factors.
The r2 (coefficient of determination) may indicate the fraction of the total
variation explained by the respective factors
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question, namely, how much of the variation in drug
membrane transport as tested with in vivo probe drugs is
caused by heritable factors? One approach to answer this
question and to differentiate between genetic and environ-
mental factors is the use of twin studies. The results of
twin studies may provide a unique basis to direct further
research [58]. If a major part of the variation in the
pharmacokinetics of probe drugs can be explained by gen-
etic factors, then further approaches like whole-genome
sequencing to search for the underlying factors may be
promising. If results from twin studies reveal no or only
moderate genetic effects, then such genome-wide screen-
ing might not be very promising or could require major
effort to achieve adequate statistical power.
We chose talinolol as a probe drug because it is not
metabolized to a relevant extent and in vitro and in vivo
studies revealed that it may be a good probe drug for
MDR1 as well as probably for MRP2 [37]. Generally, a
probe drug has great heuristic potential allowing ex-
trapolation from effects in one drug to numerous other
drugs. However, this probe drug approach has limita-
tions because in reality pharmacokinetics of every probe
drug is not dependent on just one transporter or enzyme
but probably on several, and many transporters or en-
zymes have multiple substrate binding sites with differen-
tial substrate affinities. With talinolol, we do not know
quantitatively how much of the AUC or total clearance
depends on MDR1 since data obtained in the MDR1
knockout rat [40] may be compromised by unspecific or
secondary effects of the knockout; also, other factors limit
extrapolation from rat to human.
More than usual with pharmacokinetic data, the mean
pharmacokinetic parameters of talinolol differed be-
tween the studies. Its mean oral clearance was 0.93 l/
min in our study and varied between 0.58 l/min [59] and
1.95 l/min (calculated from dose divided by given AUCin-
finity) [45] in other studies. Although this variation may
result from minor differences in the pharmaceutical
preparations, data analysis, and study populations, it
could also indicate that some not yet clearly defined en-
vironmental factors have a major influence on the
pharmacokinetics of talinolol.
To the best of our knowledge this is the first twin
study on the heritability of talinolol pharmacokinetics
as a marker of variation in drug membrane transport
activities. We observed unexpectedly small heritability.
The correlations between the siblings were nominally
even higher for DZ than for MZ twin pairs (Fig. 1b, c)
and, consistent with this, structural equation modeling re-
vealed that common and unique environmental effects
best explained the variation in talinolol oral clearance.
Mechanistically, unique environmental effects include
everything that acted randomly and not in the same
manner in both siblings, whereas common environmental
a
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Fig. 2 a, b Concentration time curves of one study day of the
50 mg talinolol study phase (a) and the 2.5 mg talinolol study
phase (b). c Correlation of the AUC7h after the administration of
50 mg and 2.5 mg talinolol. Shown are all 72 individuals who
received both dosages. AUC7h area under the curve in the first
7 hours after application
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effects may include everything that is common to the
siblings arising during pregnancy, childhood, and later life.
Such common environmental effects may include all types
of epigenetic effects but also any other factors which may
be common due to growing up in the same family and
environment.
The twin-study independent approach of Kalow et al.
[55, 56], which uses repeated drug administration, re-
vealed a low genetic component (rGC) of 0.38 and is
generally in good agreement with the result from structural
equation modeling. However, this component of 38 % in-
cludes both genetic effects and common environmental ef-
fects. This means that less (probably even much less) than
38 % of the variation is due to heritable factors. In con-
trast to the low genetic component in this study, other
studies reveal high genetic components for other
pharmacological variability, e.g., between 0.95 and 0.98
for the activity of N-acetyltransferase 2 (NAT2) [52, 55],
0.96 for plasma clearance of midazolam [60], 0.94 for the
ethinylestradiol serum AUC [60], and 0.91 for the plasma
AUC of metoprolol [51].
Several genetic polymorphisms in drug membrane
transporters have already been analyzed in relation to
talinolol pharmacokinetics. In our study, the genetic
variants of MDR1 C1236T and G2677T/A were signifi-
cantly associated with talinolol oral clearance, but this
association was weak and even not significant after
including other factors in a multifactorial analysis. For
both polymorphisms clearance was enhanced in sub-
jects heterozygously or homozygously carrying the
1236 T and 2677 T alleles, indicating higher activity of
MDR1 compared to homozygous carriers of the 1236C
or 2677G alleles. In line with this, both polymorphisms
showed a lower AUC in subjects carrying hetero- or
homozygous variants (1236 T and 2677 T or A) in an-
other independent study on the oral bioavailability of
talinolol [44]. However, two further studies found no
significant effects of C3435T and G2677T/A [45, 61] as
well as C1236T [45] on the talinolol AUC, indicating
only weak functional effects and/or big effects of other
not yet fully understood factors.
In this study we did not observe effects of some fre-
quently studied and apparently functional MRP2, MDR5,
and ABCG2 polymorphisms on talinolol clearance.
The MRP2 finding is in contrast to Haenisch et al.
[47], who reported an association of a lower AUC
(and a lower oral bioavailability) and the 1249A variant.
However, confirmation of earlier genotype–phenotype
associations was not the primary aim of the present
study and would have required a substantially bigger
sample size, particularly for the quantitatively moderate
effects.
The effects of genetic variation in efflux transporters
on talinolol pharmacokinetics may be complicated by
additional influences of genetically polymorphic influx
transporters. A study by Bernsdorf et al. reported a sig-
nificantly decreased talinolol half-life in carriers of the
*1b variant in organic anion transporter OATP1B1 [48].
The *1b variant seems to code for a protein with high
activity [62] but, in the study by Bernsdorf et al., subjects
carrying the low-activity allele *15 of OATP1B1 also
showed a decreased half-life. In line with these results,
our study revealed that heterozygous carriers of the *1b
allele (n = 21) tended to have a higher clearance com-
pared to carriers of the wild-type allele *1a (Additional
file 2) but homozygous carriers of the *1b allele (n = 4)
had a lower clearance. The lack of consistency and the
lack of a consistent effect in our study of the low activity
allele *5 do not support a relevant role for OATP1B1 in
the pharmacokinetics of talinolol.
Talinolol is a relatively hydrophilic drug and with a
pKa of 9.3, about 98 % of the molecules are positively
charged at physiological pH [50]. It is therefore a pos-
sible substrate of organic cation transporters [44]. For
this reason we studied the influence of genetic variants
in the genetically highly polymorphic transporter OCT1
on talinolol clearance. Surprisingly, although not signifi-
cant, talinolol oral clearance tended to be increased in
carriers of one or two reduced activity OCT1 alleles.
Further in vitro research is required to elucidate whether
OATP1B1 or OCT1 may enhance cellular uptake of
talinolol.
Interestingly, protein and vegetable consumption both
statistically significantly increased talinolol clearance. Our
study was not designed to elucidate the underlying sub-
stances and mechanisms but it is reasonable that the
pharmacokinetics of the mostly not metabolized drug tali-
nolol is strongly dependent on transport activities in the
intestinal mucosa and expression in these cells should de-
pend on diet.
In an additional study, a subgroup of the volunteers
received a low oral dose of 2.5 mg talinolol. The aim of
this low-dose study was to enable a comparison between
it and the 50 mg study. The so-called microdosing de-
sign has repeatedly been shown to be a valuable tool in
the drug development process [63]. Although microdos-
ing is defined by administration of doses below 100 μg,
and in this sense we did not perform microdosing, the
observations with our low range millidosing are notable.
Interestingly, we observed quite different results com-
pared to the therapeutic dose. The dose-normalized
AUC7h was only about 50 % in the low dose talinolol
group compared with the AUC from the comparable
time interval in the 50 mg talinolol group. Also, tmax was
achieved significantly earlier in the 50 mg talinolol group.
These differences were already noted by Wetterich et al.
[50]. One explanation may be that, in the high dose group,
efflux transporters like MDR1 may be saturated very early
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so drug elimination, especially due to intestinal efflux, is
delayed [50]. The very low correlation of the AUC7h for
2.5 mg and 50 mg talinolol (Fig. 2c) may similarly indicate
first that this may be one example of a substance for
which microdosing is not highly predictive for pharmaco-
kinetics in therapeutic doses and second that the relevant
transport processes and proteins involved may be different
depending on the doses. This is supported by the fact that
this correlation (Fig. 2c) was much lower than the correl-
ation between the different study days with the same dose
and between the siblings (Fig. 1d, e). In contrast to our
study, another study with another MDR1 probe drug, fex-
ofenadine, showed more rapid absorption of the drug with
the smaller dose [64]. In this other study, however, 100 μg
of fexofenadine was administered in 10 ml physiological
saline and quickly swallowed and the high dose of 120 mg
was administered as a tablet. Therefore, the different
formulations may explain the contradictory results to our
study.
Conclusions
The absorption, distribution, and elimination of talinolol
seem to be mainly determined by environmental effects.
This may indicate that the in vivo activity of MDR1 may
also be dominantly determined by environmental factors.
Some data presented in this study, however, may raise
doubts about whether or not talinolol is really a good in
vivo probe drug for MDR1. Further experimental and clin-
ical research on the role of OATP1B1 and OCT1 may be
scientifically interesting, but from our data one might sim-
ply conclude that frequent genetic polymorphisms with
dominant effects on talinolol pharmacokinetics do not
exist.
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